PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
PepGen Inc. (PEPG)
Company Research
Source: GlobeNewswire
- Enrollment completed for PGN-EDO51 5 mg/kg cohort in CONNECT1-EDO51 Phase 2 clinical trial in DMD patients. The Company expects to announce preliminary data from the 5 mg/kg dose cohort in mid-2024 – - CONNECT2-EDO51 Phase 2 clinical trial in DMD patients open in the U.K. - Company believes this study could potentially support accelerated approval - - FREEDOM-DM1 Phase 1 clinical trial enrolling DM1 patients with preliminary data for at least the 5 mg/kg dose cohort expected in the second half of 2024 - - Gross proceeds of approximately $80 million from February 2024 follow-on offering extends projected operating cash runway into 2026 - BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for the fourth quarter and full year ended Decem
Show less
Read more
Impact Snapshot
Event Time:
PEPG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PEPG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PEPG alerts
High impacting PepGen Inc. news events
Weekly update
A roundup of the hottest topics
PEPG
News
- PepGen Inc. (NASDAQ: PEPG) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $26.00 price target on the stock.MarketBeat
- PepGen Inc. (NASDAQ: PEPG) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $20.00 price target on the stock.MarketBeat
- PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights [Yahoo! Finance]Yahoo! Finance
- PepGen Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsGlobeNewswire
- PepGen to Participate in Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
PEPG
Earnings
- 5/14/24 - Beat
PEPG
Sec Filings
- 5/17/24 - Form 4
- 5/17/24 - Form 144
- 5/14/24 - Form 10-Q
- PEPG's page on the SEC website